Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN)

Supernus Pharmaceuticals, Inc. is a biopharmaceutical company specializing in the development and commercialization of treatments for central nervous system (CNS) diseases. The company focuses on a diverse neuroscience portfolio, including approved therapies for attention-deficit hyperactivity disorder (ADHD), Parkinson’s disease (PD), postpartum depression (PPD), epilepsy, migraine, cervical dystonia, and chronic sialorrhea. Supernus also advances a pipeline of novel product candidates targeting various CNS disorders, leveraging proprietary formulation technologies to enhance efficacy, improve patient adherence, and reduce side effects. The company’s strategic acquisitions, such as the 2025 purchase of Sage Therapeutics, Inc., have expanded its portfolio and commercial capabilities, particularly in the treatment of depression and other neuropsychiatric conditions.

Supernus Pharmaceuticals, Inc. generates revenue primarily through the sale of its proprietary CNS drugs in the U. S. market, with additional income derived from licensing agreements, royalties, and collaborations for international commercialization. Key commercial products include Qelbree for ADHD, GOCOVRI for dyskinesia and "OFF" episodes in Parkinson’s disease, ZURZUVAE for postpartum depression, and Trokendi XR and Oxtellar XR for epilepsy and migraine prevention. The company also markets APOKYN and ONAPGO for hypomobility in Parkinson’s disease, XADAGO for "OFF" episodes, MYOBLOC for cervical dystonia and chronic sialorrhea, and Osmolex ER. Revenue is further bolstered by milestone payments and royalties from partnerships, such as its collaboration with Biogen for ZURZUVAE and licensing agreements with Shionogi for zuranolone in Japan, South Korea, and Taiwan. The majority of sales are made to pharmaceutical wholesalers, specialty pharmacies, and distributors, which then supply healthcare providers and patients.

The company operates through the following segments:

• Neurology: This segment focuses on the development and commercialization of treatments for neurological disorders, including Parkinson’s disease and epilepsy. Key products include GOCOVRI, APOKYN, ONAPGO, XADAGO, Trokendi XR, and Oxtellar XR. The segment also encompasses the company’s proprietary technologies, such as Microtrol, Solutrol, and EnSoTrol, which are used to enhance drug formulations and improve patient outcomes. Supernus markets these products through specialized sales forces targeting movement disorder specialists, neurologists, and other healthcare providers.

• Psychiatry: This segment is dedicated to psychiatric conditions, including ADHD and postpartum depression. Leading products include Qelbree for ADHD and ZURZUVAE for PPD, the latter of which is co-commercialized with Biogen in the U. S. The segment also includes pipeline candidates like SPN-820 for treatment-resistant depression and SPN-443 for ADHD. Sales efforts are directed toward psychiatrists, pediatricians, primary care physicians, obstetricians-gynecologists, and advanced practice providers. The acquisition of Sage Therapeutics significantly strengthened this segment by adding zuranolone-based therapies and expanding the company’s footprint in depression and neuropsychiatric disorders.

Supernus Pharmaceuticals, Inc. holds a competitive position in the CNS therapeutics market, distinguished by its focus on underserved and complex neurological and psychiatric conditions. In ADHD, Qelbree competes with both stimulant and non-stimulant therapies, including generics like Adderall XR and Vyvanse, as well as branded products such as Intuniv and Strattera. Its non-stimulant profile and once-daily dosing provide a differentiated option for patients and prescribers. In Parkinson’s disease, GOCOVRI is the only FDA-approved treatment for both dyskinesia and "OFF" episodes, positioning it uniquely against competitors like Inbrija and NOURIANZ. The company’s epilepsy and migraine portfolio, led by Trokendi XR and Oxtellar XR, benefits from extended-release formulations that improve adherence and tolerability compared to immediate-release alternatives. ZURZUVAE, the first oral treatment for postpartum depression, faces competition from standard antidepressants but offers a rapid, 14-day treatment course, a significant advantage in this underserved market. Supernus’s proprietary technologies and strategic partnerships further enhance its competitive edge by enabling the development of novel formulations and expanding global reach.

Supernus Pharmaceuticals, Inc. serves a broad customer base, primarily through pharmaceutical wholesalers, specialty pharmacies, and distributors. Its three largest customers—Cencora, Inc., Cardinal Health, Inc., and McKesson Corporation—collectively accounted for over 76% of total product revenue in 2025. These intermediaries supply the company’s products to pharmacies, hospitals, and other healthcare providers, including federal and state entities. Direct sales to physicians and hospitals are also a component of its distribution model, particularly for products like MYOBLOC. The company’s commercial efforts target specialized healthcare providers, such as movement disorder specialists for Parkinson’s therapies, psychiatrists and pediatricians for ADHD treatments, and obstetricians-gynecologists for postpartum depression therapies. Through collaborations with partners like Biogen and Shionogi, Supernus also reaches international markets, extending its customer base beyond the U. S.